Table 1 Patients’ characteristics
From: Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes
Description | Total (N = 16) |
|---|---|
Demographic characteristics | |
 Age, median (Range) | 67.5 (51, 91) |
 Sex, n (%) | |
  Female | 8 (50.0%) |
 Living status, n (%) | |
  Living with husband/wife/partner | 12 (75.0%) |
  Living alone | 3 (18.7%) |
  Living with parents/family or friends | 1 (6.3%) |
 Work status, n (%) | |
  Retired | 13 (81.3%) |
  Not working due to MDS | 2 (12.5%) |
  Disability | 1 (6.3%) |
 Race, n (%) | |
  Caucasian | 15 (93.7%) |
  Black/African American | 1 (6.3%) |
 Highest level of education, n (%) | |
  College or university | 7 (43.8%) |
  Some years of college | 5 (31.3%) |
  Graduation or professional degree | 2 (12.5%) |
  Some high school | 1 (6.3%) |
  High school diploma or general educational development | 1 (6.3%) |
Clinical characteristics | |
 Years since diagnosis, Median (Range) | 3.6 (0.25, 50.8) |
 IPSS risk category, n (%) |  |
  Intermediate-1-risk | 9 (56.2) |
  Low-risk | 7 (43.8) |
 MDS Subtypea, n (%) | |
  Refractory Anemia with Ring Sideroblasts (RARS) | 7 (43.8) |
  Refractory Cytopenia with Multilineage Dysplasia (RCMD) | 6 (37.5) |
  MDS Unclassified (MDS-U) | 2 (12.5) |
  Refractory Cytopenia with Unilineage Dysplasia (RCUD) | 1 (6.3) |
  MDS associated with del(5q) including the 5q- syndrome | 1 (6.3) |
 ECOG performance status, n (%) | |
  0 | 7 (43.8) |
  1 | 9 (56.2) |
 Chronic diseases other than MDS, n (%) | 8 (50.0) |
  Cardiovascular | 6 (75.0) |
  Endocrinological/Nutritional | 3 (37.5) |
  Rheumatological | 2 (25.0) |
  Gastroenterological | 1 (12.5) |
  Hematological | 1 (12.5) |
  Gynecological | 1 (12.5) |
  Dermatological | 1 (12.5) |
 Current prescribed pharmacological treatment n (%) | |
  Erythropoietin | 3 (18.8) |
  Deferasirox | 3 (18.8) |
  Decitabine | 2 (12.5) |
  Deferoxamine | 2 (12.5) |
  Azacitidine | 2 (12.5) |
  Granulocyte-colony stimulating factor | 1 (6.3) |
  Prednisone | 1 (6.3) |
  Rituximab | 1 (6.3) |
  Coenzyme Q10 | 1 (6.3) |
  Furosemide | 1 (6.3) |
 Previous pharmacological treatment n (%) | |
  Erythropoietin | 10 (62.5) |
  Lenalidomide | 4 (25.0) |
  Azacitidine | 2 (12.5) |
  Filgrastim | 2 (12.5) |
  Hypomethylating agents | 1 (6.3) |
  Granulocyte-colony stimulating factor | 1 (6.3) |
  Deferasirox | 1 (6.3) |
  Danazol | 1 (6.3) |